Patients with high-frequency deafness and/or substantial residual hearing across frequencies might benefit from combined electro-acoustic stimulation. The Hybrid-L electrode was designed to address the issues of both hearing conservation and effective electrical stimulation in those recipients. The electrode with 22 contacts should be inserted through the round window membrane, and covers approximately 270° of the basal turn of the cochlear. This insertion length is equivalent to the one seen in many patients using the former Nucleus straight electrode. Twenty-four patients with low-frequency thresholds of 60 dB or better, up to 500 Hz, were implanted with a Hybrid-L device in a clinical trial at the Medical University of Hannover. Another group of 8 recipients with less residual hearing was included under extended inclusion criteria. Residual hearing was conserved in the majority of cases. One patient had a loss of more than 30 dB, but hearing partially recovered after 9 months. The median loss in all patients was 10 dB in both the Hybrid group and the extended group. Patients were able to use the residual hearing postoperatively to the same extent as preoperatively. In the Hybrid mode (cochlear implant + ipsilateral hearing aid), patients showed a significant improvement of 21% (p = 0.002) in speech understanding in quiet using the Freiburger Monosyllabic Word Test compared to the preoperative scores under aided conditions with their hearing aid. The Oldenburg Sentence Test in noise showed a remarkable average improvement of 10.2 dB (p < 0.001) compared to the preoperative hearing aid only mode. An additional improvement could be seen in the combined mode using an additional contralateral hearing aid. Recipients with a shorter duration of high-frequency hearing loss showed a larger benefit than those with a longer duration of hearing loss. Hearing conservation using the Hybrid-L electrode and a given surgical technique is possible with high probability in patients with high-frequency deafness or pantonal hearing loss. The use of the residual acoustic hearing offers specific advantages, especially for understanding speech in noise and for spatial hearing.

Due to improved technology, cochlear implant (CI) candidacy has been widened towards patients with usable residual hearing in the low frequency range. These patients might benefit from additional acoustic amplification provided that residual hearing can be preserved with cochlear implantation. To provide a high probability of hearing preservation, a new electrode array was designed and developed at the Medizinische Hochschule Hannover. This ‘Hybrid-L’ electrode array has 22 electrodes spread over 15 mm with an overall insertion depth of 16 mm. The straight electrode with modiolus facing contacts is designed for a round window insertion. It shall provide the full range of the currently most advanced Nucleus CI system. A temporal bone study demonstrated the favorable insertion characteristics and minimized trauma to intracochlear structures. Compared to standard CI electrodes especially no basilar membrane perforation could be found. So far, 4 patients have been implanted and residual hearing could be preserved. One patient was fitted and showed a marked additional benefit from the electroacoustic stimulation compared to either acoustic or electrical stimulation alone. These results are very encouraging towards a concept of reliable hearing preservation with cochlear implantation.

Background: The success of cochlear implantation may be further improved by minimizing implantation trauma. The physical trauma of implantation and subsequent immunological sequelae can affect residual hearing and the viability of the spiral ganglion. An ideal electrode should therefore decrease post-implantation trauma and provide support to the residual spiral ganglion population. Combining a flexible electrode with cells producing and releasing protective factors could present a potential means to achieve this. Mononuclear cells obtained from bone marrow (BM-MNC) consist of mesenchymal and hematopoietic progenitor cells. They possess the innate capacity to induce repair of traumatized tissue and to modulate immunological reactions. Methods: Human bone marrow was obtained from the patients that received treatment with biohybrid electrodes. Autologous mononuclear cells were isolated from bone marrow (BM-MNC) by centrifugation using the Regenlab™ THT-centrifugation tubes. Isolated BM-MNC were characterised using flow cytometry. In addition, the release of cytokines was analysed and their biological effect tested on spiral ganglion neurons isolated from neonatal rats. Fibrin adhesive (Tisseal™) was used for the coating of silicone-based cochlear implant electrode arrays for human use in order to generate biohybrid electrodes. Toxicity of the fibrin adhesive and influence on insertion, as well on the cell coating, was investigated. Furthermore, biohybrid electrodes were implanted in three patients. Results: Human BM-MNC release cytokines, chemokines, and growth factors that exert anti-inflammatory and neuroprotective effects. Using fibrin adhesive as a carrier for BM-MNC, a simple and effective cell coating procedure for cochlear implant electrodes was developed that can be utilised on-site in the operating room for the generation of biohybrid electrodes for intracochlear cell-based drug delivery. A safety study demonstrated the feasibility of autologous progenitor cell transplantation in humans as an adjuvant to cochlear implantation for neurosensory restoration. Conclusion: This is the first report of the use of autologous cell transplantation to the human inner ear. Due to the simplicity of this procedure, we hope to initiate its widespread utilization in various fields.